Assessment Status |
Pre submission consultation scheduled |
HTA ID |
25010 |
Drug |
Durvalumab |
Brand |
Imfinzi® |
Indication |
Durvalumab (Imfinzi®) is indicated as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy. |
Rapid review commissioned |
14/02/2025 |
Rapid review completed |
06/03/2025 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
27/03/2025 |